Clinical Trial Update: CNI-1493 for Treatment of Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of CNI-1493 for moderate to severe Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CNI-1493

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Crohn Disease | Phase 2 | Status: TERMINATED